Chromosome fragility in patients with Fanconi anaemia: Diagnostic implications and clinical impact

Journal of Medical Genetics

Volumn 48, Issue 4, 2011, Pages 242-250

  Castella, Maria ^a,b   Pujol, Roser ^a,b   Callén, Elsa ^a,b   Ramírez, Maria J ^a,b   Casado, Joséé A ^b,c   Talavera, Maria ^d   Ferro, Teresa ^d   Muñoz, Arturo ^d   Sevilla, Julián ^e   Madero, Luis ^e   Cela, Elena ^f   Beléndez, Cristina ^f   de Heredia, Cristina Díaz ^g   Olivé, Teresa ^g   de Toledo, José Sánchez ^g   Badell, Isabel ^h   Estella, Jesús ⁱ   Dasí, Ángeles ^j   Rodríguez Villa, Antonia ^k   Gómez, Pedro ^k   Tapia, María ^l   Molinés, Antonio ^m   Figuera, Ángela ⁿ   Bueren, Juan A ^b,c   Surrallés, Jordi ^a,b   more..

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^c CIEMAT   (Spain)

^d HOSPITAL RAMÓN Y CAJAL   (Spain)

^e HOSPITAL INFANTIL UNIVERSITARIO NIÑO JESÚS   (Spain)

^f HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^g HOSPITAL MATERNO INFANTIL VALL D HEBRON   (Spain)

^h HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

ⁱ HOSPITAL SANT JOAN DE DÉU   (Spain)

^j HOSPITAL UNIVERSITARIO LA FE   (Spain)

^k HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^l Hospital General de La Palma   (Spain)

^m HOSPITAL UNIVERSITARIO MATERNO INFANTIL DE CANARIAS   (Spain)

ⁿ HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BUTADIENE DIEPOXIDE; MITOMYCIN C;

ARTICLE; CELL SURVIVAL; CELL VIABILITY; CHROMOSOME FRAGILITY; CONTROLLED STUDY; DISEASE SEVERITY; DNA CROSS LINKING; FANCONI ANEMIA; GENOMIC INSTABILITY; HUMAN; MAJOR CLINICAL STUDY; MOSAICISM; ONSET AGE; PRIORITY JOURNAL; PROGNOSIS; T LYMPHOCYTE;

CHROMOSOME FRAGILITY; CROSS-LINKING REAGENTS; EPOXY COMPOUNDS; FANCONI ANEMIA; HUMANS; MITOMYCIN; MOSAICISM; PHENOTYPE;

EID: 79953678081     PISSN: 00222593     EISSN: 14686244     Source Type: Journal    
DOI: 10.1136/jmg.2010.084210     Document Type: Article

References (35)

1. Fanconi G. Familiäre infantile perniziosaartige Anämie (perniziöses Blutbild und Konstitution). Jahrbuch für Kinderheilkunde und physische 1927;117:257-80.
2. Joenje H, Patel KJ. The emerging genetic and molecular basis of Fanconi anaemia. Nat Rev Genet 2001;2:446-57.
3. Callen E, Casado JA, Tischkowitz MD, Bueren JA, Creus A, Marcos R, Dasi A, Estella JM, Munoz A, Ortega JJ, de Winter J, Joenje H, Schindler D, Hanenberg H, Hodgson SV, Mathew CG, Surralles J. A common founder mutation in FANCA underlies the world's highest prevalence of Fanconi anemia in Gypsy families from Spain. Blood 2005;105:1946-9.
4. Tipping AJ, Pearson T, Morgan NV, Gibson RA, Kuyt LP, Havenga C, Gluckman E, Joenje H, de Ravel T, Jansen S, Mathew CG. Molecular and genealogical evidence for a founder effect in Fanconi anemia families of the Afrikaner population of South Africa. Proc Natl Acad Sci U S A 2001;98:5734-9.
5. Whitney MA, Saito H, Jakobs PM, Gibson RA, Moses RE, Grompe M. A common mutation in the FACC gene causes Fanconi anaemia in Ashkenazi Jews. Nat Genet 1993;4:202-5.
6. Moldovan GL, D'Andrea AD. How the fanconi anemia pathway guards the genome. Annu Rev Genet 2009;43:223-49.
7. Wang W. Emergence of a DNA-damage response network consisting of Fanconi anaemia and BRCA proteins. Nat Rev Genet 2007;8:735-48.
8. Vaz F, Hanenberg H, Schuster B, Barker K, Wiek C, Erven V, Neveling K, Endt D, Kesterton I, Autore F, Fraternali F, Freund M, Hartmann L, Grimwade D, Roberts RG, Schaal H, Mohammed S, Rahman N, Schindler D, Mathew CG. Mutation of the RAD51C gene in a Fanconi anemia-like disorder. Nat Genet 2010;42:406-9.
9. Auerbach AD. Fanconi anemia and its diagnosis. Mutat Res 2009;668:4-10.
10. Kennedy RD, D'Andrea AD. The Fanconi Anemia/BRCA pathway: new faces in the crowd. Genes Dev 2005;19:2925-40.
11. Casado J, Callen E, Jacome A, Rio P, Castella M, Lobitz S, Ferro T, Munoz A, Sevilla J, Cantalejo A, Cela E, Cervera J, Sanchez-Calero J, Badell I, Estella J, Dasi A, Olive T, Jose Ortega J, Rodriguez-Villa A, Tapia M, Molines A, Madero L, Segovia JC, Neveling K, Kalb R, Schindler D, Hanenberg H, Surralles J, Bueren JA. A comprehensive strategy for the subtyping of patients with Fanconi anaemia: conclusions from the Spanish Fanconi Anemia Research Network. J Med Genet 2007;44:241-9.
12. Niedernhofer LJ, Lalai AS, Hoeijmakers JH. Fanconi anemia (cross)linked to DNA repair. Cell 2005;123:1191-8.
13. Schroeder TM. [Cytogenetic and cytologic findings in enzymopenic panmyelopathies and pancytopenias. Familial myelopathy of Fanconi, glutathionereductase deficiency anemia and megaloblastic B12 deficiency anemia] (In German). Humangenetik 1966;2:287-316.
14. Schuler D, Kiss A, Fabian F. [Chromosome studies in Fanconi's anemia] (In Hungarian). Orv Hetil 1969;110:713-20 passim.
15. Sasaki MS. Is Fanconi's anaemia defective in a process essential to the repair of DNA cross links? Nature 1975;257:501-3.
16. Auerbach AD. A test for Fanconi's anemia. Blood 1988;72:366-7.
17. Auerbach AD. Diagnosis of Fanconi Anemia by Diepoxybutane Analysis. Current Protocols in Human Genetics. Hoboken, NJ: John Wiley & Sons, Inc., 1994: Unit 8.7.1.
18. Soulier J, Leblanc T, Larghero J, Dastot H, Shimamura A, Guardiola P, Esperou H, Ferry C, Jubert C, Feugeas JP, Henri A, Toubert A, Socie G, Baruchel A, Sigaux F, D'Andrea AD, Gluckman E. Detection of somatic mosaicism and classification of Fanconi anemia patients by analysis of the FA/BRCA pathway. Blood 2005;105:1329-36.
19. Kwee ML, Poll EH, van de Kamp JJ, de Koning H, Eriksson AW, Joenje H. Unusual response to bifunctional alkylating agents in a case of Fanconi anaemia. Hum Genet 1983;64:384-7.
20. Lo Ten Foe JR, Kwee ML, Rooimans MA, Oostra AB, Veerman AJ, van Weel M, Pauli RM, Shahidi NT, Dokal I, Roberts I, Altay C, Gluckman E, Gibson RA, Mathew CG, Arwert F, Joenje H. Somatic mosaicism in Fanconi anemia: molecular basis and clinical significance. Eur J Hum Genet 1997;5:137-48.
21. Gross M, Hanenberg H, Lobitz S, Friedl R, Herterich S, Dietrich R, Gruhn B, Schindler D, Hoehn H. Reverse mosaicism in Fanconi anemia: natural gene therapy via molecular self-correction. Cytogenet Genome Res 2002;98:126-35.
22. Youssoufian H. Natural gene therapy and the Darwinian legacy. Nat Genet 1996;13:255-6.
23. Kutler DI, Singh B, Satagopan J, Batish SD, Berwick M, Giampietro PF, Hanenberg H, Auerbach AD. A 20-year perspective on the International Fanconi Anemia Registry (IFAR). Blood 2003;101:1249-56.
24. Rio P, Meza NW, Gonzalez-Murillo A, Navarro S, Alvarez L, Surralles J, Castella M, Guenechea G, Segovia JC, Hanenberg H, Bueren JA. In vivo proliferation advantage of genetically corrected hematopoietic stem cells in a mouse model of Fanconi anemia FA-D1. Blood 2008;112:4853-61.
25. Raya A, Rodriguez-Piza I, Guenechea G, Vassena R, Navarro S, Barrero MJ, Consiglio A, Castella M, Rio P, Sleep E, Gonzalez F, Tiscornia G, Garreta E, Aasen T, Veiga A, Verma IM, Surralles J, Bueren J, Belmonte JC. Disease-corrected haematopoietic progenitors from Fanconi anaemia induced pluripotent stem cells. Nature 2009;460:53-9.
26. Dufour C, Svahn J. Fanconi anaemia: new strategies. Bone Marrow Transplant 2008;41(Suppl 2):S90-5.
27. Joenje H, Arwert F, Eriksson AW, de Koning H, Oostra AB. Oxygendependence of chromosomal aberrations in Fanconi's anaemia. Nature 1981;290:142-3.
28. Pagano G, Degan P, d'Ischia M, Kelly FJ, Nobili B, Pallardo FV, Youssoufian H, Zatterale A. Oxidative stress as a multiple effector in Fanconi anaemia clinical phenotype. Eur J Haematol 2005;75:93-100.
29. Nordenson I. Effect of superoxide dismutase and catalase on spontaneously occurring chromosome breaks in patients with Fanconi's anemia. Hereditas 1977;86:147-50.
30. Pang Q, Andreassen PR. Fanconi anemia proteins and endogenous stresses. Mutat Res 2009;668:42-53.
31. Bogliolo M, Cabre O, Callen E, Castillo V, Creus A, Marcos R, Surralles J. The Fanconi anaemia genome stability and tumour suppressor network. Mutagenesis 2002;17:529e38.
32. Hales BF. DNA repair disorders causing malformations. Curr Opin Genet Dev 2005;15:234-40.
33. Kachnic LA, Li L, Fournier L, Willers H. Fanconi anemia pathway heterogeneity revealed by cisplatin and oxaliplatin treatments. Cancer Lett 2010;292:73-9.
34. Pulliam-Leath AC, Ciccone SL, Nalepa G, Li X, Si Y, Miravalle L, Smith D, Yuan J, Li J, Anur P, Orazi A, Vance GH, Yang FC, Hanenberg H, Bagby GC, Clapp DW. Genetic disruption of both Fancc and Fancg in mice recapitulates the hematopoietic manifestations of Fanconi anemia. Blood 2010;116:2915-20.
35. Wilson JB, Yamamoto K, Marriott AS, Hussain S, Sung P, Hoatlin ME, Mathew CG, Takata M, Thompson LH, Kupfer GM, Jones NJ. FANCG promotes formation of a newly identified protein complex containing BRCA2, FANCD2 and XRCC3. Oncogene 2008;27:3641-52.